港股异动丨中国中药收跌4.57% 大摩料其股价将在未来30天下跌

Core Viewpoint - China Traditional Chinese Medicine (0570.HK) experienced a decline of 4.57%, closing at HKD 2.09, with a trading volume of HKD 95.08 million and a market capitalization of HKD 10.5 billion. The company announced a projected loss for the fiscal year ending December 31, 2025, marking a significant shift from profit to loss, with expected losses between RMB 350 million to RMB 500 million, compared to a profit of RMB 20.77 million in the previous year. Adjusted net profit is anticipated to decrease by 45% to 55%, down from RMB 636 million in the prior year [1][1][1] Financial Performance - The company expects to report a loss for the fiscal year 2025, which would be the first loss since 2013 [1] - The adjusted net profit is projected to decline by 45% to 55%, with the previous year's figure being approximately RMB 636 million [1] Analyst Ratings - Morgan Stanley has updated its risk-reward rating for China Traditional Chinese Medicine, lowering earnings forecasts for 2026 to 2030 by 5% to 12% and reducing the target price from HKD 1.5 to HKD 1.4, maintaining a "Reduce" rating [1][1] - The firm believes there is a 70% to 80% probability that the stock price will decline over the next 30 days, primarily due to the profit warning [1][1] Market Outlook - The company faces challenges due to a shrinking market size, and it has not disclosed specific plans for market expansion through internal resources or acquisitions [1] - The market currently has low visibility regarding the company's performance in 2026, indicating further potential downside for the stock price [1]